Skip to main
MNKD

MannKind (MNKD) Stock Forecast & Price Target

MannKind (MNKD) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 57%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

MannKind is positioned for strong growth with recent label updates, potential for $150M in annual revenue, and strong investment in in-house innovation and development of new therapies for high-burden diseases. Their primary revenue driver is their Tyvaso DPI royalty income, with potential for growth in the IPF and PPF segments. MNKD's acquisitions and expansion into the pediatric market show their commitment to providing innovative and convenient therapies for underserved diseases. Valuation based on DCF and probability-adjusted EPS analyses supports their current price target and potential for growth, but investors should be aware of potential risks such as product commercial and supply chain risk. As a result, the rating for MNKD shares is Buy. Overall, MannKind has a strong financial standing and a positive outlook for future growth.

Bears say

MannKind is facing potential competition and challenges to their patent protection, which could weaken their competitive position and limit market potential. Their revenue from Furoscix may also be affected by the recent approval of Boehringer Ingelheim's Jascayd, the first new therapy for IPF in a decade. Clinical and regulatory risks also exist for their pipeline programs, and a negative trial readout or regulatory decision could delay commercialization and limit their market potential.

MannKind (MNKD) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 57% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MannKind (MNKD) Forecast

Analysts have given MannKind (MNKD) a Buy based on their latest research and market trends.

According to 7 analysts, MannKind (MNKD) has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MannKind (MNKD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.